Brachytherapy technology now available nationwide

TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product?s developer, and BrachySciences.

TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product’s developer, and BrachySciences.

“This agreement places new technology that can improve prostate cancer treatment outcomes directly in the hands of doctors to benefit their patients,” said Robert G. Mills, Envisioneering president.

According to Mills, TargetScan addresses unmet treatment planning and brachytherapy seed placement needs of radiation oncologists. In addition to eliminating prostate movement during treatments, the system offers improved 3-D imaging, with views of both sagittal and transverse planes.

Related Videos
Blurred image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Jacob Taylor, MD, MPH, answers a question during a Zoom video interview
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Matthew J. Ziegelmann, MD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.